安旭生物：股东马华祥拟减持不超0.94%公司股份

Core Viewpoint - Anxu Bio announced that its major shareholder, Ma Huaxiang, plans to reduce his stake in the company due to personal financial needs, with a potential sale of up to 1.2 million shares, representing 0.94% of the total share capital, between December 11, 2025, and March 10, 2026 [1] Summary by Categories - Shareholder Actions - Ma Huaxiang, a shareholder holding more than 5% of the company, intends to sell up to 1.2 million shares [1] - The reduction in shares will occur through centralized bidding transactions [1] - Timeline and Conditions - The planned reduction period is set from December 11, 2025, to March 10, 2026 [1] - The selling price will be determined based on market conditions [1] - The implementation of this reduction plan carries uncertainties [1]